Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination

Study Design, Oversight and Ethics

A double-blind, randomized, placebo-controlled, stratified, case-driven phase 3 clinical trial recruited adult participants in medically stable condition from 48 sites in eight Havana municipalities. Participants recruited March 8–31, 2021 by community family doctors provided written informed consent. The trial adheres to the principles of the Helsinki Declaration and to the International Council for Harmonization’s Good Clinical Practice guidelines. The Cuban Ministry of Health’s Central Research Ethics Committee was appointed ad hoc for this trial. It approved the protocol (Clinical Trials IFV/COR/09 number, RPCEC00000354) and the consent forms. (Details on procedures are provided in the protocol and Supplementary Information (SI) available upon publication).

The Cuban National Clinical Trials Coordinating Center (CENCEC) monitored the trial in terms of adherence to the protocol and Good Clinical Practice as well as data accuracy. An unblinded independent data and safety monitoring board (IDSMB) continuously monitored safety and conducted interim analysis (IA). The trial was designed, conducted and sponsored by the Finlay Vaccine Institute. Data analysis and interpretation were performed by the research team. The SOBERANA 02 team collected data and contributed to their interpretation.

Participants, randomization and data blinding

Volunteers aged 19–80 years were screened for eligibility at clinical sites. A full list of exclusion criteria is provided with the study protocol available upon publication. Three groups were formed to receive two doses of SOBERANA 02 (group A); two doses of SOBERANA 02 followed by a third dose of SOBERANA Plus (heterologous scheme, group B); and placebo (two doses) administered 28 days apart. Randomization into study arms (A and B) and placebo was done on day 0 at a 1:1:1 ratio using a site stratified random and previously defined risk strata (19–64 years without risk comorbidities, 19–64 years with risk comorbidities and ≥65 years). Participants at risk of severe COVID-19 disease were defined in the protocol available upon publication. In the event of a medical emergency requiring acute intervention, unmasking was planned after approval by the responsible investigator and IDSMB knowledge.

Trial vaccines/placebo

SOBERANA 02 antigen is the recombinant SARS-CoV-2 RBD (25 μg), chemically conjugated to TT in a molar ratio ∼6/1 and adsorbed on 500 μg alumina [2]. SOBERANA Plus was develop as a universal booster; the antigen is dimeric RBD (50 μg) adsorbed on 1250 μg alumina [11]. The placebo contained all ingredients except the active principle. Vaccine and placebo were indistinguishable to ensure product masking. Both were stored at 2° to 8°C and distributed daily to clinical sites by specialized logistics personnel.

Safety

AEs were classified as solicited and unsolicited; as mild, moderate and severe; and vaccine related or non-related. Frequencies were calculated after each vaccine/placebo dose: solicited local and systemic, during 7 days; unsolicited, during 28 days; leading to protocol discontinuation, demanding medical attention or classified as serious, during 30 days. IDSMB continuously monitored COVID-19 and severe COVID-19 cases. Safety was evaluated in the “Safety Population”(SP): participants receiving at least one dose of the vaccine candidates or placebo.

Efficacy

The primary endpoint was VE in preventing occurrence of symptomatic COVID-19 confirmed by positive SARS-CoV-2 RT-PCR nasopharyngeal swab (RT-PCR), with onset at least 14 days after the last injection in the per-protocol population (PPP). Primary endpoint was judged blinded by COVID-19 hospital doctors, reviewed by specially trained doctors and finally by the study’s Principal Investigator (PI).

COVID-19 symptomatic disease was considered if participants had at least one major symptom or sign or two minor symptoms (major signs or symptoms: dyspnea, oxygen saturation ≤92%, persistent thoracic pain, neurological disorders, clinical or radiographic evidence of pneumonia; minor symptoms: fever, chills, myalgia, headache, sore throat, running nose, diarrhea/vomiting, myalgia, malaise, cough, dysgeusia/anosmia). RT-PCR was conducted by the SARS CoV-2 national reference laboratory at the Pedro Kourí Tropical Medical Institute, Havana, Cuba. Participants with symptoms or reporting direct contact with a positive RT-PCR person were referred to a COVID-19 hospital designated by the Ministry of Public Health and advised to show their “study identity card”. After a positive RT-PCR, they were hospitalized and followed daily to assess symptom severity, until hospital discharge upon negative RT-PCR and symptom resolution.

VE at the primary endpoint was evaluated across risk strata for severe disease (19–64 years without risk comorbidities; 19–64 years with risk comorbidities; and ≥65 years), sex (female/male), and skin color (white, black and mixed-race). Secondary outcomes for VE were severe systemic confirmed COVID-19 disease (serious or critical), defined by one of the following criteria: polypnea; x-ray infiltration/condensation, pulmonary echography; oxygen saturation ≤90% or assisted mechanical ventilation (serious disease), acute respiratory distress syndrome or evidence of septic shock (critical disease). (Other secondary outcomes are included in SI upon publication).

Statistical analysis

To evaluate the primary VE endpoint, the trial was designed with the hypothesis that the risk of symptomatic disease is reduced >60% compared to placebo group. The lower limit of the 95% confidence interval (CI) was ≥30%, which points to the rejection of the null hypothesis (that the efficacy of either vaccination scheme is ≤30%)[12]. VE was calculated as percentage reduction in the hazard ratio (HR) as VE=100 × (1 –HR) %, in the vaccine groups as compared with placebo, separately, with HR estimated from a stratified Cox proportional hazards model. The design required achieving 90% power (and 2.5% 1-sided type I error) to detect a HR of 0.4 (VE >60% to reduce the risk of symptomatic disease compared to placebo), with a null hypothesis HR of 0.7. VE bounds were derived using a Lan-DeMets O’Brien-Fleming approximation spending function. Two interim analyses (IA) were planned at detection of 53 and 106 symptomatic cases meeting the primary outcome definition more than 14 days after the last dose of the corresponding schedule.

A stopping criterion due to unacceptable toxicity (frequency >1%) was evaluated iteratively, with a Bayesian algorithm (SI upon publication).

Trial Population

Recruited participants (44 031) underwent randomization (mean age: 48 years, 52% female, 18% ≥65 years, 28% 19–64 years with comorbidities) as follows: group A: 14 679 (two doses, SOBERANA 02), group B: 14 677 (three doses heterologous schedule) and group C: 14 675 (placebo) (Fig. 1). Demographic characteristics were balanced between placebo and intervention groups (Table 1). The racial or ethnic proportions were representative of Cuban demographics. Evidence of previous SARS-CoV-2 infection at baseline as detected by serologic rapid test was present in 0.4% of participants.

• Download figure
• Open in new tab

Figure 1. Enrollment and Outcomes.

§ Safety population included all the participants who had undergone randomization and received at least one dose of the SOBERANA 02 vaccine or placebo. For SOBERANA 02, two-dose schedule efficacy was measure for individuals receiving both doses of vaccine or placebo. For SOBERANA 02 + SOBERANA Plus, three-dose heterologous schedule efficacy considered individuals receiving the planned three doses or two doses of placebo The primary end point was analyzed in the per-protocol population (PPP)* which included participants who were seronegative at baseline, had no major protocol deviations and were not confirmed as positive COVID19 before day 14 after the last dose (considered as Time 0 for follow-up) Footnote: §Exclusion criteria: acute infection disease on previous 7 days, mental disorders, known history of COVID-19, history of hypersensitivity to components of the formulations, tetanus toxoid vaccine in the last 3 months, previous SARS-CoV-2 vaccine, any immunomodulatory therapy in the last month, pregnancy, puerperium or breastfeeding, uncontrolled chronic diseases, HIV, unstabilized malignant disease or under chemotherapy and/or radiotherapy. *”Lost of follow-up” and “discontinued intervention” were not excluded from the analysis

173 participants withdrew consent and did not receive the second dose and 286 did not receive the third dose. Participants were excluded when detected positive by RT-PCR before receiving the second dose (407 participants) and before the third dose (123 participants). Primary efficacy and safety were analyzed in PPP and SP respectively. The primary VE analysis included 42 557 participants receiving the first injection: group C (placebo) (14 303), group A (14 371) and group B (13 883); 1 474 participants were excluded from the PPP (Fig. 1): placebo group (372), group A (308) and group B (794). Median follow-up was 50 days (range, 0–156) and 121 days (range, 0–136) after the third dose.

Safety

Solicited AEs at injection site occurred more frequently in the vaccine group than in the placebo group after both the first dose (7.7%, vs. 2.6%) and the second dose (1.9%, vs. 0.44%) (Fig. 2). After the third dose, frequency of subjects with AEs at injection site was 0.3%. In the vaccine groups (A + B), injection site events were predominantly grade 1 in severity and lasted a median of 1 day after the first and second dose, and 2 days after the third dose. The most common injection site AE was pain after injection (2.6% vs. 8.2% in placebo and vaccine, respectively at any time). Delayed injection site reactions were noted in 21 participants (0.05%) after the first dose, 5 (0.01%) after the second dose and 1 after the third dose (0.01%). Reactions were characterized by erythema, induration, and warmth, swelling and pain, and all resolved over the following day (IQR percentiles 25-75: (0.5-2)) Solicited systemic AEs occurred more often in the vaccine groups than in the placebo group after both the first dose (2.0% vs. 1.6%) and the second dose (0.8% vs. 0.2%) and were 0.1% after the third dose. Their severity in the vaccine groups changed slightly; for grade 2 events, from 6.5% after the first dose to 8.8% after the second dose; for grade 3, from 0.6% to 0.4%. Solicited systemic AEs in the vaccine groups lasted a median of 1 day after the first and second doses, and 2 days after the third dose.

• Download figure
• Open in new tab

Figure 2. Solicited Local and Systemic Adverse Events.

The percentage of participants with solicited local and systemic AEs during the 7 days after each vaccination (any grade: mild, moderate, severe) compared by treatment: 1^st and 2^nd dose SOBERANA 02 vs Placebo ; 3^rd dose SOBERANA Plus vs Soberana 02 (average from 1^st and 2^nd dose)

Both solicited injection-site (7.1% vs. 5.1%) and systemic AEs (2.4% vs. 2.2%) were more common among younger participants (19-64 years) than in those ≥65 years. group. AE frequency reported during the 28 days following each injection was similar in all groups: grade 3 AEs in the placebo group (3.8%), in the vaccine groups (3.4% and 4.2%, for groups A and B, respectively) and serious AEs (7.9%, 6.7% and 6.7% in placebo, A and B groups respectively).

All-cause mortality was unbalanced, 9 and 11 (0.1% for group A and B, among vaccine recipients) and 24 (0.2%) in placebo recipients.

Efficacy

The final analysis of the two-dose schedule detected 198 cases of COVID-19: 43 in vaccine group A (0.8 per 1000 person-years; 95% CI, 0.6–1.1) and 155 in the placebo group (2.7 per 1000 person-years; 95% CI, 2.3–3.2), indicating 71.0% VE (95% CI, 58.9– 79.1%; P<0.001) for prevention of symptomatic SARS-CoV-2 infection as compared to placebo (Fig. 4A).

• Download figure
• Open in new tab

Figure 3. Cumulative Incidence of Symptomatic COVID-19 in the Per-Protocol Population.

The timing of surveillance for symptomatic COVID-19 began on day 14 after the last dose (marked as Time 0 in figures) in the per-protocol population) through approximately the first 3 months of follow-up.

• Download figure
• Open in new tab

Figure 4. Vaccine Efficacy of SOBERANA 02 in specific subgroups in the Per-Protocol Population.

A) two-dose schedule, SOBERANA 02; B) Heterologous three-dose schedule (2 x SOBERANA 02 + SOBERANA Plus). Vaccine Efficacy is defined as 1 minus the relative risk (full regime (A or B) vs. placebo). Risk strata (19–64 years without risk comorbidities, 19–64 years with risk comorbidities and ≥65 years). Participants at risk of severe COVID-19 disease were defined in the protocol (available as Supplementary Information)

The final analysis of the three-dose schedule registered 170 cases of COVID-19: 15 cases in vaccine group B, (0.1 per 1000 person-years; 95% CI, 0.1 to 0.1) and 155 cases in the placebo group, indicating 92.4% VE (95% CI, 86.9–95.6%; P<0.001) for prevention of symptomatic SARS-CoV-2 infection as compared to placebo (Fig. 4B).

For the two-dose schedule, VE for prevention of severe COVID-19 was 63.0% (2/14731 cases in group A vs 6/14303 cases in placebo), and for heterologous three-dose schedule, 100% (0/13883 cases in group B vs 6/14303 cases in placebo). VE for prevention of COVID-19 death was 59.0% for the two-dose schedule (3/14731 cases in group A vs 8/14303 cases in placebo) and 100% for heterologous three-dose schedule (0/13883 cases in group B vs 8/14303 cases in placebo).